Alnylam Pharmaceuticals
ALNY
#799
Rank
โ‚น2.960 T
Marketcap
โ‚น22,127
Share price
2.47%
Change (1 day)
-47.30%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): โ‚น103.11 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚น4.80 Billion. In 2025 the company made an earning of โ‚น61.87 Billion, an increase over its 2024 earnings that were of -โ‚น22.43 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) โ‚น103.11 B66.64%
2025 โ‚น61.87 B-375.96%
2024 -โ‚น22.43 Billion-24.59%
2023 -โ‚น29.74 Billion-67.84%
2022 -โ‚น92.46 Billion36.93%
2021 -โ‚น67.52 Billion-8.04%
2020 -โ‚น73.42 Billion-15.66%
2019 -โ‚น87.06 Billion12.23%
2018 -โ‚น77.57 Billion62.91%
2017 -โ‚น47.62 Billion17.78%
2016 -โ‚น40.43 Billion43.44%
2015 -โ‚น28.19 Billion60.69%
2014 -โ‚น17.54 Billion98.2%
2013 -โ‚น8.85 Billion
2011 -โ‚น5.22 Billion27.48%
2010 -โ‚น4.1 Billion-10.92%
2009 -โ‚น4.6 Billion95.77%
2008 -โ‚น2.35 Billion
2006 -โ‚น3.77 Billion-9.13%
2005 -โ‚น4.14 Billion34.74%
2004 -โ‚น3.08 Billion36.79%
2003 -โ‚น2.25 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
โ‚น1.477 T 1,280.17%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น681.73 B 536.67%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น491.85 B 359.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น12.47 Billion-111.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น4.52 Billion-104.22%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น7.61 Billion-107.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น152.81 B 42.71%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-โ‚น15.19 Billion-114.18%๐Ÿ‡บ๐Ÿ‡ธ USA